Derek Lowe 评 β-catenin 降解研究:合成过快会让降解策略失效
Think Before You Degrade
Derek Lowe 评述一项靶向蛋白降解(TPD)研究,该研究用 dTag 系统在 β-catenin 上测试降解效果,发现蛋白水平升高的原因不同,决定了降解能否奏效。稳定化突变使 β-catenin 水平升高 3 到 5 倍时仍可被降解压低,而多西环素诱导的过表达系统把水平提高约五倍后,降解基本失败,合成速率压过了降解速率。他认为 TPD 项目需要仔细考虑靶蛋白的合成速率、降解途径和半衰期。
This paper really give targeted protein degradation (TPD) people something to think about. The exciting thing about TPD is that it provides (in many cases, for the first time) a pharmacological means to lower the amount of a target protein without doing anything to the genomic or translational machinery. The protein is degraded once it’s out in the cytosol, and this zapping-with-a-degrader-thunderbolt mode of action is indeed something new. There are numerous example in the literature over the last few years that show the differences that can be seen between this mechanism and good ol’ chemical inhibition, with many of the TPD alternatives showing more profound effects.
But you have to wonder what the effect is of the protein levels of your target, and that includes its background rate of synthesis, its normal degradation pathways and its normal half-life, and what happens when (as is often the case with cancer cells) you’re targeting a protein that’s being overexpressed in the first place because of the disease. The paper linked above studies such a target, beta-catenin, and that’s a good choice. It’s very much a clinically relevant cancer target, and it’s also been very difficult to cleanly target it with small-molecule mechanisms. The more modern bifunctional degraders would seem to be a very promising approach.
Of course, to get those to work you need one end of the degrader to be something that does a good job of binding to beta-catenin, and that’s not so easy. This paper gets around that by engineering a model system with the dTag degradation machinery, where a mutated form of FKBP12 is fused to the beta-catenin, making it vulnerable to the specific chemical ligand that binds to that newly added mutant binding site. The authors threw in a green fluorescent protein, GFP, while they were at it so they could watch what was going on - it’s already been established that you can stick such things onto the C-terminal end of beta-catenin while maintaining its function, but the authors checked to make sure of this, as one certainly should.
This idea also lets you interrogate different mechanisms for the “too much beta-catenin” state of various tumor types. One way to get that is to increase the protein’s half-life in the cells, and those control experiments just mentioned are crucial to getting that part to work - it’s also been shown that tagging some proteins with such chemical biology widgets can affect their stability and cellular half-lives. Fortunately, in this case the team was able to get an engineering beta-catenin that still behaved as it should. And it’s already known that mutations in a particular area of the beta-catenin sequence mess up its usual degradation pathways and allow it to accumulate, so there’s you chance to test this part of the problem. They looked at three of these, which produced 3x to 5x greater levels of the protein.
The other way to cause a protein to pile up, though, is to jack up its rate of production while leaving its degradation machinery just the way it was. And there are beta-catenin-driven tumor cells with that situation, too. Here the “oversynthesis” route was done by engineering a doxycycline-driven induced expression system, which cranked levels up about fivefold. Both of these were then hit with the dTag induced degradation system, and the differences were profound.
Put briefly, the stabilizing mutations were targetable by degradation, and beta-catenin levels could still be driven down by such means. But the overexpression systems were different: trying to lower beta-catenin levels by degradation in those cases basically failed, because it appears that the rate of synthesis could always outcompete whatever enhanced degradation could be thrown at the problem.
This is something that TPD project are going to have to think about very carefully. Depending on the disease that you’re targeting, this could give you hope that your degradation strategy will work or give you real evidence that it probably won’t. Some cancer situations will be complicated by the way that some of the tumor tissue might be using one of these mechanisms for high oncogene product levels while other cells might be using the other! The data in this paper argue very strongly that these factors shouldn’t be ignored; our clinical success rates are low enough already without walking into what could be avoidable trouble.
来源:In the Pipeline · science.org